NEW YORK, January 13, 2017 /PRNewswire/ --
This morning, Stock-Callers.com draws attention to three Biotech equities to see how they have fared at yesterday's closing
bell: Clovis Oncology Inc. (NASDAQ: CLVS), Galena Biopharma Inc. (NASDAQ: GALE), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD).
These companies harness cellular and biomolecular processes to develop technologies and products that combat debilitating and
rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and provide safer, cleaner and
more efficient industrial manufacturing processes. Download the free research reports on these stocks today:
http://stock-callers.com/registration
Clovis Oncology
Boulder, Colorado headquartered Clovis Oncology Inc.'s shares soared 8.43%, finishing
Thursday's trading session at $53.49. A total volume of 3.46 million shares was traded, which was
above their three months average volume of 2.09 million shares. The stock has advanced 43.37% in the past month, 63.68% in the
previous three months, and 20.42% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving
averages by 41.37% and 118.55%, respectively. Moreover, shares of Clovis Oncology, which focuses on acquiring, developing, and
commercializing anti-cancer agents in the US, Europe, and internationally, have a Relative
Strength Index (RSI) of 74.57.
On December 21st, 2016, research firm WallachBeth reiterated its 'Hold' rating on the Company's
stock with an increase of the target price from $22 a share to $49 a
share.
On January 03rd, 2017, Clovis announced that it has commenced an underwritten public offering of
shares of its common stock to raise aggregate proceeds of approximately $175 million. Clovis
intends to use the net proceeds of the offering for general corporate purposes, including commercial planning and sales, and
marketing expenses associated with the launch of Rubraca™ in the US and, if approved by the European Medicines Agency, in
Europe, funding of its development programs, general and administrative expenses, acquisition or
licensing of additional product candidates or businesses and working capital. See our free and comprehensive research report on
CLVS at:
http://stock-callers.com/registration/?symbol=CLVS
Galena Biopharma
On Thursday, shares in San Ramon, California-based Galena Biopharma Inc. recorded a trading
volume of 661,487 shares and the stock ended the session 5.45% lower at $1.91. The stock is trading
32.96% below its 50-day moving average. Shares of the Company, which focuses on developing and commercializing oncology
therapeutics that address major unmet medical needs, have an RSI of 34.04.
On December 28th, 2016, Galena Biopharma announced that it has confirmed the regulatory pathway
to advance GALE-401 into a pivotal, Phase 3 trial. After a productive meeting with the US FDA, the Company has confirmed the
development program and proposed clinical trial are appropriate for a New Drug Application filing using the 505(b)(2) regulatory
pathway. The Company expects to finalize the Phase-3 clinical trial protocol and initiate the trial in Q2, 2017. GALE free
research report PDF is just a click away at:
http://stock-callers.com/registration/?symbol=GALE
ACADIA Pharma
At the closing bell yesterday, shares in San Diego, California headquartered ACADIA
Pharmaceuticals Inc. ended 6.39% higher at $31.78. A total volume of 3.17 million shares was
traded, which was above their three months average volume of 2.70 million shares. The stock has advanced 25.71% in the last one
month, 23.27% in the previous three months, and 10.19% on an YTD basis. The Company's shares are trading above their 50-day and
200-day moving averages by 15.38% and 1.67%, respectively. Furthermore, shares of ACADIA Pharma, which focuses on the development
and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have an RSI
of 59.55.
On December 20th, 2016, ACADIA Pharma announced positive top-line results from its Phase II
exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis (AD Psychosis). Pimavanserin has
been approved by the US FDA for hallucinations and delusions associated with Parkinson's disease psychosis, and it currently is
being studied in several other disease states. Register for free on Stock-Callers.com and download the latest research report on
ACAD at:
http://stock-callers.com/registration/?symbol=ACAD
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA